AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16285996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 600 mg/day
Number of subjects: 60
Study 16285996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 900 mg/day
Number of subjects: 60
Study 16285996 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 60
Study 12064848 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (FMT)
Number of subjects: 21
Study 12064848 — intervention group
Group type: COMPARATOR
Intervention: Control (FMC)
Number of subjects: 21
Study 12064848 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 21
Study 10414671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3‐4 mcg/kg)
Number of subjects: 27
Study 10414671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7587754 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR)
Number of subjects: 249
Study 7587754 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 249
Study 2107013 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine started before symptoms
Number of subjects: 42
Study 2107013 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine started after symptoms
Number of subjects: 42
Study 2107013 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 6776161 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indoprofen
Number of subjects: 40
Study 6776161 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg indoprofen
Number of subjects: 40
Study 6776161 — intervention group
Group type: COMPARATOR
Intervention: 0.5 Gm lysine acetylsalicylate (ASA)
Number of subjects: 40
Study 6776161 — intervention group
Group type: COMPARATOR
Intervention: 1.5 Gm lysine acetylsalicylate (ASA)
Number of subjects: 40
Study 31889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counselling
Number of subjects: 105
Study 31889350 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study 31544383 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal cake‐separated moxibustion with new‐type moxibustion device combined with bladder function exercise
Number of subjects: 68
Study 31544383 — intervention group
Group type: COMPARATOR
Intervention: Bladder function exercise
Number of subjects: 68
Study 28304092 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 100
Study 28304092 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 100
Study 28304092 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 100
Study 26406475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psychoeducational support program (3 sessions)
Number of subjects: 155
Study 26406475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study 24065377 — intervention group
Group type: EXPERIMENTAL
Intervention: AVNRT
Number of subjects: 50
Study 24065377 — intervention group
Group type: EXPERIMENTAL
Intervention: AVRT
Number of subjects: 50
Study 24065377 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 24065377 — intervention group
Group type: COMPARATOR
Intervention: AVNRT, AVRT, Control
Number of subjects: 50
Study 21332573 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) + Praziquantel (PZQ)
Number of subjects: 32
Study 21332573 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (ABZ) alone
Number of subjects: 32
Study 19583645 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-enhancing educational intervention (two 90-minute sessions between 33rd-35th weeks of pregnancy)
Number of subjects: 133
Study 19583645 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy-enhancing educational intervention
Number of subjects: 133
Study 17149760 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of paclitaxel followed by 4 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (n = 10)
Number of subjects: 39
Study 17149760 — intervention group
Group type: EXPERIMENTAL
Intervention: chemotherapy with simultaneous weekly trastuzumab for 24 weeks (n = 29)
Number of subjects: 39
Study 17149760 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatment regimens
Number of subjects: 39
Study 15233841 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 173
Study 15233841 — intervention group
Group type: EXPERIMENTAL
Intervention: All-round, functional training
Number of subjects: 173
Study 15233841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of resistance and all-round, functional training
Number of subjects: 173
Study 15233841 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 173
Study 12130958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tube feeding
Number of subjects: 60
Study 12130958 — intervention group
Group type: COMPARATOR
Intervention: Small-bowel tube feeding
Number of subjects: 60
Study 10622504 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 47
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder role
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inquirer role
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal topics (Experiment 2)
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical topics (Experiment 1)
Number of subjects: 0
Study 7779309 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit memory tests (cued recall and recognition)
Number of subjects: 0
Study 2154047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam treatment
Number of subjects: 0
Study 6781170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol-induced abortion
Number of subjects: 20
Study 31726202 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Allen's test
Number of subjects: 54
Study 31726202 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Princeps Pollicis Artery ultrasound
Number of subjects: 54
Study 31726202 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Barbeau test
Number of subjects: 54
Study 30391389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (100 IU/kg body weight administered in divided doses)
Number of subjects: 1836
Study 30391389 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose heparin (50 IU/kg body weight)
Number of subjects: 1836
Study 30391389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (100 IU/kg body weight)
Number of subjects: 1836
Study 27509251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (PrEP)
Number of subjects: 1200
Study 25671951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 30 mg/kg tranexamic acid
Number of subjects: 137
Study 25671951 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of tranexamic acid
Number of subjects: 137
Study 22742439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI); details on dosage and duration not specified.
Number of subjects: 0
Study 20231034 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2332
Study 20231034 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 2332
Study 18166122 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing Yoga plus Touch (RYT)
Number of subjects: 40
Study 18166122 — intervention group
Group type: COMPARATOR
Intervention: Relaxing Yoga (RY)
Number of subjects: 40
Study 18166122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RY and RYT
Number of subjects: 40
Study 15894479 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled HFA beclomethasone (Ventolair)
Number of subjects: 11
Study 12515670 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH small dose (0.3 IU.kg(‐1).d(‐1))
Number of subjects: 36
Study 12515670 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH large dose (0.6 IU.kg(‐1).d(‐1))
Number of subjects: 36
Study 12515670 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 36
Study 9488531 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide-enriched total parenteral nutrition (TPN)
Number of subjects: 28
Study 9488531 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.5 g of amino acids kg(‐1) day(‐1))
Number of subjects: 28
Study 7999488 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg kg‐1 i.m.
Number of subjects: 48
Study 7999488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg kg‐1 orally
Number of subjects: 48
Study 7999488 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 48
Study 2904310 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 40
Study 2904310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29744721 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 44
Study 29744721 — intervention group
Group type: COMPARATOR
Intervention: Biodentine
Number of subjects: 44
Study 28324049 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intensive metabolic intervention
Number of subjects: 83
Study 28324049 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week intensive metabolic intervention
Number of subjects: 83
Study 28324049 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care (control)
Number of subjects: 83
Study 26436473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Number of subjects: 700
Study 26436473 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Number of subjects: 700
Study 26436473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen
Number of subjects: 700
Study 26436473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 24223219 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotionally salient words
Number of subjects: 45
Study 24223219 — intervention group
Group type: COMPARATOR
Intervention: Neutral words
Number of subjects: 45
Study 21187525 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Jasper Jumper (JJ)
Number of subjects: 46
Study 21187525 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaire-type facemask
Number of subjects: 46
Study 21187525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 18358927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 2 weeks for 6 weeks followed by 12 weeks of continued treatment
Number of subjects: 56
Study 18358927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18358927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab in open-label extension phase
Number of subjects: 56
Study 16343858 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 800 mg pre-operatively (Group A)
Number of subjects: 47
Study 16343858 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin 400 mg pre-operatively plus two doses of 200 mg 24 h apart (Group B)
Number of subjects: 47
Study 12544006 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (40 g of alcohol daily for 3 weeks)
Number of subjects: 11
Study 12544006 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (40 g of alcohol daily for 3 weeks)
Number of subjects: 11
Study 12544006 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits (Dutch gin) (40 g of alcohol daily for 3 weeks)
Number of subjects: 11
Study 12544006 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 11
Study 10916812 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 7
Study 8726169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 102
Study 8726169 — intervention group
Group type: COMPARATOR
Intervention: Control group (other anti-platelet drugs and/or warfarin potassium)
Number of subjects: 102
Study 8219631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 10
Study 8219631 — intervention group
Group type: COMPARATOR
Intervention: Argon laser treatment
Number of subjects: 10
Study 2874411 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 411
Study 2874411 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 411
Study 2874411 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with CMF
Number of subjects: 411
Study 29734461 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 1
Study 29734461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 27058593 — intervention group
Group type: EXPERIMENTAL
Intervention: Full correction (FC) single vision lenses (n = 75)
Number of subjects: 150
Study 27058593 — intervention group
Group type: COMPARATOR
Intervention: +0.50D undercorrection (UC) single vision lenses (n = 75)
Number of subjects: 150
Study 25948674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical saffron (Crocus sativus L) gel
Number of subjects: 50
Study 25948674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23620937 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX-UE 10), treatment given once a week for 4 weeks.
Number of subjects: 80
Study 23620937 — intervention group
Group type: COMPARATOR
Intervention: Medication group with erkangning syrup, administered 3 times a day for 4 weeks.
Number of subjects: 80
Study 23620937 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group, no intervention mentioned.
Number of subjects: 80
Study 20814189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.03 mg/kg/day
Number of subjects: 133
Study 20814189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.06 mg/kg/day
Number of subjects: 133
Study 20814189 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone + Oxandrolone (Ox) / Placebo (Pl)
Number of subjects: 133
Study 18360665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% dyclonine spraying anesthesia
Number of subjects: 300
Study 18360665 — intervention group
Group type: EXPERIMENTAL
Intervention: FRILJET local cryoanesthesia and pulp vitality test agent
Number of subjects: 300
Study 18360665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 300
Study 16840441 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of screening information as frequencies (n = 83)
Number of subjects: 166
Study 16840441 — intervention group
Group type: COMPARATOR
Intervention: Presentation of screening information as percentages (n = 86)
Number of subjects: 166
Study 16840441 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetricians
Number of subjects: 166
Study 12920470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 g every 4 hours, not exceeding 8 doses)
Number of subjects: 210
Study 12920470 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (continuous infusion)
Number of subjects: 210
Study 10832518 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial copy of tennis ball trajectory
Number of subjects: 0
Study 10832518 — intervention group
Group type: COMPARATOR
Intervention: Referent group allowed to see the actual referent trajectory
Number of subjects: 0
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Fat
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated Fat
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fat
Number of subjects: 662
Study 9095079 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Number of subjects: 662
Study 7939948 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg mebendazole (locally produced)
Number of subjects: 196
Study 7939948 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg mebendazole (original)
Number of subjects: 196
Study 7939948 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole (original)
Number of subjects: 196
Study 7939948 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole (original)
Number of subjects: 196
Study 3780818 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus slow release nifedipine
Number of subjects: 12
Study 3780818 — intervention group
Group type: COMPARATOR
Intervention: Theophylline plus placebo
Number of subjects: 12
Study 28295204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers given instructions on spatial thinking and guidance
Number of subjects: 41
Study 28295204 — intervention group
Group type: COMPARATOR
Intervention: Mothers asked to play as usual (Control)
Number of subjects: 41
Study 28295204 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed dyads (children)
Number of subjects: 41
Study 28295204 — intervention group
Group type: COMPARATOR
Intervention: Control dyads (children)
Number of subjects: 41
Study 27611039 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg dexmedetomidine
Number of subjects: 60
Study 27611039 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg dexmedetomidine
Number of subjects: 60
Study 27611039 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg dexmedetomidine
Number of subjects: 60
Study 27611039 — intervention group
Group type: COMPARATOR
Intervention: Control group (bupivacaine 0.5% + normal saline)
Number of subjects: 60
Study 25555183 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management program (10 min diaphragmatic breathing and 15 min progressive muscle relaxation twice per day)
Number of subjects: 53
Study 25555183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study 22104016 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person nutrition education and supermarket point-of-purchase healthful shopping program
Number of subjects: 153
Study 22104016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 153
Study 20693886 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐esterase inhibitor (100 U/kg)
Number of subjects: 20
Study 20693886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18842789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg quercetin
Number of subjects: 12
Study 18842789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg (‐)‐epicatechin
Number of subjects: 12
Study 18842789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg epigallocatechin gallate
Number of subjects: 12
Study 18842789 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 16076683 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 32
Study 16076683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 32
Study 16076683 — intervention group
Group type: COMPARATOR
Intervention: Whole study population (regardless of intervention)
Number of subjects: 32
Study 12059865 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 30
Study 12059865 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 30
Study 12059865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10406443 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition education
Number of subjects: 1309
Study 10406443 — intervention group
Group type: COMPARATOR
Intervention: General written nutrition advice
Number of subjects: 1309
Study 8768870 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/IGF‐I treatment (0.34 mg GH twice daily and 5.0 mg IGF‐I twice daily)
Number of subjects: 66
Study 8768870 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/IGF‐I treatment
Number of subjects: 66
Study 8768870 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study 1555623 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 11)
Number of subjects: 22
Study 1555623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 22
Study 3908494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, 1 tablet 3 times per day for 5 days)
Number of subjects: 11
Study 3908494 — intervention group
Group type: COMPARATOR
Intervention: Root-planing alone
Number of subjects: 11
Study 3908494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 11
Study 31486700 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of fluvastatin daily for 6 weeks
Number of subjects: 20
Study 31486700 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20
Study 27990769 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing from the lingual aspect
Number of subjects: 46
Study 27990769 — intervention group
Group type: COMPARATOR
Intervention: Brushing from the buccal aspect
Number of subjects: 46